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Abstract We recently described the design of Escherichia
coli K12 and Salmonella enterica sv Typhimurium to
display the gangliomannoside 3 (GM3) antigen on the cell
surface [1]. We report here the fucosylation of modified
lipooligosaccharide in a recombinant E.coli strain with a
truncated lipid A core due to deletion of the core
glycosyltransferases genes waaO and waaB. This trunca-
ted structure was used as a scaffold to assemble the Lewis
Y motif by consequent action of the heterologously
expressed β-1,4 galactosyltransferase LgtE (Neisseria
gonorrheae), the β-1,3 N-acetylglucosaminyltransferase
LgtA and the β-1,3 galactosyltransferase LgtB from
Neisseria meningitidis, as well as the α-1,2 and α-1,3
fucosyltransferases FutC and FutA from Helicobacter
pylori. We show the display of the Lewis Y structure by
immunological and chemical analysis.
Keywords Bacterial glycosylation . Glycoengineering .
Fucosylation . Lewis Y. Chimeric LOS
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Introduction
Carbohydrates are common molecular tools to mediate
interactions between cells. Eukaryotes as well as bacteria
and archaea synthesise numerous oligo- and polysaccha-
ride structures, many of which are located on the cell
surface. In bacteria, surface carbohydrates are important
structural motives involved in many biological processes
including virulence, phage protection, and host immunity.
The main classes of carbohydrate-containing extracellular
compounds are capsular polysaccharides, lipo-oligo/poly-
saccharides, and to a certain extent, outer membrane
glycoproteins [2, 3]. The unravelling of the respective
biosynthetic pathways has opened new strategies to
engineer bacterial surfaces. One aspect of this field of
research is the engineering of non-pathogenic bacterial
strains to display pathogen-related motifs. These newly
generated strains can then be used to initiate and study an
immune response against carbohydrate structures without
any additional harmful effects of the pathogenic strain.
Additionally, bacteria can be engineered to express and
display carbohydrate motives of a mammalian host for
subsequent use in pathogen neutralisation after infection
of the host [4, 5]. The engineering of heterologous
carbohydrate structures on bacterial cell surfaces in vivo
requires several steps: The provision of a donor substrate
for the glycosyltransferase(s), the availability of an
acceptor structure and the possibility to export the in vivo
created foreign carbohydrate structure to the cell surface.
The last aspect often prevents the display of engineered
oligosaccharides on the cell surface. For example,
although the biosynthesis of the lipo-oligosaccharide core
of Escherichia coli is well known, the details of the
exportation pathway from the cytoplasm to the outer-
membrane are not completely elucidated. Recently, it
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could be demonstrated that LPS transport involves the
periplasmic protein LptA, the cytosolic protein LptB and
the inner membrane proteins LptC, LptF and LptG, which
constitute an ABC transporter with accessory proteins [6].
The nascent LPS molecule is then targeted to the outer
leaflet of the outer membrane by the outer membrane
proteins LptD/LptE [7–9].
To create an acceptor substrate for heterologously
expressed glycosyltransferases, bacteria with a truncated
LOS structure can be obtained by deletion of genes
encoding glycosyltransferases involved in the first steps
of the lipid A core synthesis. The heterologous expres-
sion of glycosyltransferases able to act on such truncated
LOS of Escherichia coli R1 allowed surface display of
globotriaose (Gb3), lac-N-neotetraose (LnNT), and gan-
gliosides GM1 and GM3 [4]. The resulting strains were
used as neutralizing bio-agents of the Shiga toxin (Stx)
and enterotoxic E. coli [5]. Another possibility is to build
the heterologous carbohydrate structure on the lipid linker
undecaprenylphosphate, with a subsequent transfer of this
structure to a full lipid A core by the O-antigen ligase
WaaL. For example, the overexpression of Haemophilus
influenzae genes encoding glycosyltransferases in E. coli
resulted in the endogenous synthesis of a recombinant
LOS carrying Haemophilus LPS motifs [10]. Altogether,
these data show that the lipid A export system of E. coli
has a certain flexibility towards its substrate and is able to
transport foreign structures to the outer membrane.
However, none of the chimeric LOS structures reported
above contain fucose, an important monosaccharide
involved in cell recognition. On the host side, fucose
forms part of a target for a number of pathogens such as
Pseudomonas aeruginosa, or Campylobacter jeujuni [11,
12]. On the bacterial side, fucose is for example present on
the gastric pathogen Helicobacter pylori.
Our recent work focused on the glyco-engineering of E.
coli to produce recombinant oligosaccharides [11]. The
technology is based on the internalisation of β-galactosides
such as lactose followed by endogenous glycosylation
when glycosyltransferases from other bacteria were
expressed recombinantly. With this system, we successively
achieved the synthesis of fucosylated oligosaccharides
including the human Lewis X and H antigens [13–16].
Additionally, the co-expression of α1,2- and α1,3- fucosyl-
transferases of H. pylori led to the production of oligosac-
charides carrying the Lewis Y antigen [17], which is a
structural motif of the lipooligosaccharide of H. pylori [18],
and a tumor-associated antigen in humans [19].
In the present report, we addressed the fucosylation of the
LOS of Escherichia coli K12 with α1,2- and α1,3- fucosyl-
transferases of H. pylori. A double mutant over-expressing a
β-galactosyltransferase of Neisseria gonorrhoea was designed
in order to exhibit a terminal lactosyl motif at the distal moiety
of lipid A. The recombinant enzymes previously used in our
lab to produce fucosylated oligosaccharides from lactose were
over-expressed in that strain in order to glycosylate the
lactosyl-lipidA core. Chemical analyses and immunological
assays were performed and attested for synthesis and
exportation of the Lewis Y epitope Fucα-2Galβ-4[Fucα-3]
GlcNAcβ-3Gal (Fuc = fucose, Gal = galactose, GlcNAc =
N-acetylglucosamine) amongst other glycoforms.
Materials and methods
Bacterial strains and growth conditions
A summary of bacterial strains used in this study can be found
in Table 1. Bacteria were grown in Luria-Bertani (LB)
medium (10 g/l Bacto tryptone, 5 g/l Bacto yeast extracts,
5 g/l NaCl). LB agar plates were supplemented with 1.5%
(w/v) agar. Antibiotics were used at the following final
concentrations: Tetracyclin 10 μg/ml, ampicillin 100 μg/ml,
kanamycin 50 μg/ml, chloramphenicol 25 μg/ml.
Construction of the E. coli K-12 ΔwcaJΔwaaOΔwaaB
strain LPS1
To inactivate wcaJ, primers (a+b) (Table 1) were used for
PCR amplification of 0.64 kb of DNA flanking the 5′ end
of wcaJ from JM107, whereas primers (c+d) were used for
PCR amplification of 1.27 kb of DNA flanking the 3′ end
of wcaJ. The reverse sequence of primer (c) was contained
in primer (b), allowing a fusion of both DNA fragments by
PCR amplification with primers (a+d). Fused DNA of
1.91 kb containing a truncated wcaJ was cloned into
BamHI site of the suicide plasmid pKO3. The resulting
recombinant suicide plasmid pKO3-J containing a trun-
cated wcaJ sequence and flanking DNA to guaranty
recombination was transformed into TA1 cells, mutants
were obtained according to author’s instructions [20].
Positive clones were screened by PCR with primers (a)
and (c). The inactivation of waaO and waaB is described
elsewhere [1].
Construction of plasmids pSUlgtA and pSU-lgtAfutC
Plasmid pLNT1T [16] was digested with NdeI to remove
lgtB, thus ligated, providing pBBR-lgtA. LgtA was then
obtained by KpnI and XbaI digestion for the cloning into
pSU2718 to give pSU-lgtA. FutC was obtained by KpnI
and SalI digestion of plasmid pEXT20futC [14] and sub-
cloned into pBluescript KS, thus giving pBS-futC. This
plasmid was then digested with XbaI to obtain futC
flanked by two XbaI sites, allowing a cloning into XbaI
site of pSU-A to give pSU-lgtAfutC.
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Cell-based ELISA
Bacterial cultures that had been induced overnight with
0.6 mM IPTG were equalized to 2 OD600/ml with PBS.
Flat-bottom ELISA plates were coated with 50 μL of
cells and fixed by addition of 20 μL of formaldehyde for
30 min at room temperature. Afterwards, the formalde-
hyde was removed and unspecific binding was blocked
by addition of 1% (w/v) BSA in PBS for 1 h at room
temperature. The blocking agent was then removed and
the cells were incubated for 1 h at 4°C with anti-Lewis Y
antibody (Abcam) in 0.1% (w/v) BSA in PBS. After four
washing steps with 0.05% Tween-20/PBS, the bound
anti-Lewis-Y antibody was detected by incubation of the
cells with an anti-mouse-IgM-HRP conjugate (Santa
Cruz) for 45 min at room temperature. Unbound HRP-
conjugate was washed away with 0.05% Tween-20/PBS
in four washing steps before the cells were resuspended
in 200 μl ABTS solution (2,2′-azino-bis(3-ethylbenzthia-
zoline-6-sulphonic acid, final concentration 1 mM in
70 mM phosphocitrate buffer pH 4.2 with addition of 1%
H2O2). Vmax was determined by recording the color
development at 405 nm for 5 min in a SpectraMaxPlus
(Molecular Devices).
Electrophoretic analysis of chimeric LOS by SDS-PAGE
and immunological detection
The equivalent of 1 OD600 of exponentially growing
induced cultures with 0.6 mM IPTG was pelleted and
resuspended in 500 μl 0.065 M Tris–HCl pH 6.8, 2% SDS
(w/v), 5% β- Mercaptoethanol (v/v), 10% Glycerin (v/v),
0.05% Bromophenol blue (w/v) and lysed for 5 min at
95°C. After cooling to room temperature, proteins were
digested by addition of proteinase K (Roche, final concen-
tration 0.4 mg/ml) for 1 h at 60°C. Equal volumes of each
sample were then separated on a 17% Tris-Tricine-PAGE
and stained with silver as described [26].
To detect LewisY structures in the chimeric LOS
after gel electrophoresis, a monoclonal anti-LewisY
antibody (Abcam) was used. Bound anti-LewisY was
visualised with a goat-anti-mouse-IgM-HRP conjugate
(Santa Cruz) and ECL (Amersham) as recommended by
the manufacturer.
Table 1 Bacterial strains, plasmids and oligonucleotides used in this study
Escherichia coli strains
Name Genotype and phenotype Source or reference
DH5α SupE44 ΔlacU169 (Φ80lacZΔM15) hsdR17 recA1 endA1
gyrA96 thi-1 relA1
[21]
JM107 endA1 gyrA96 thi hsdR17 SupE44 relA1λ- Δ(lac-proAB)
[F′ traD36 proAB+ lacIq lacZΔM15]
DSM; [22]
TA01 JM 107 ΔnanA [23]
LPS1 TA01 ΔwcaJΔwaaOB [1]
H type II LPS1 with pBBRlgtE, pSUlgtAfutC, pWKSlgtB This work
LX LPS1 with pBBRlgtE, pSUlgtA, pWKSlgtB, pBSfutA This work
LY LPS1 with pBBRlgtE, pSUlgtAfutC, pWKSlgtB, pBSfutA This work
Plasmids
Plasmid Genotype Source or reference
pKO3 Suicide plasmid, temperature-sensitive pSC101 replication origin,
sacB (levansucrase)
[20]
pKO3-BO Truncated waaOB genes and flanking DNA cloned into pKO3 This work
pBBRlgtE TetR, bhr derivative, N. gonorrhoeae lgtE cloned into pBBR1MCS-3 [1]
pBSfutA AmpR, pbr322 derivative, H. pylori futA cloned into pBlue Script II KS [11]
pWKSlgtB KanR, pWKS130 derivative carrying lgtB [24]
pSU2718 CamR, pACYC184 derivative. [25]
pSUlgtA N. meningitidis lgtA cloned into pSU2718 This work
pSUlgtAfutC H. pylori futC cloned into pSUlgtA This work
Oligonucleotides (5′→3′)
a CAAGGATCCAGATGACAAATCTAAAAAAGCGCGA
b TGCGTGCGGACGTGGACCGACAATCCGTTTCGCGTCCT
CGACCAG
c ATTGTCGGTCCACGTCCGCACC
d TTAATTTGGATCCAATCGGGTTACCTACGGAGC
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Isolation of lipooligosaccharides
Isolation of LOS was carried out by phenol/chloroform/
petrol ether as reported [27], except that it was recovered
from the phenol phase by precipitation with 6 volumes of
diethyl ether/acetone (1:5 v/v) as described [28].
Preparation of de-O-acylated LPS
De-O-acylation was obtained by conventional mild
hydrazinolysis except that hydrazine-hydrate was used
instead of anhydrous hydrazine. The solution (20 mg
LOS/ml) was stirred at 37°C for 2 h. De-O-acylated LOS
was recovered from the hydrazine phase by precipitation
with 15 volumes of ice-cold acetone. The pellet was
recovered by centrifugation, washed with acetone and
air-dried.
Mass spectrometry analysis
MALDI-MS spectra of the sample were obtained with an
Autoflex Bruker MALDI-TOF spectrometer. DHB (2,
5-Dihydroxybenzoic acid, SIGMA) was used as a matrix.
The De-O-acylated LOS sample was dissolved in water at a
concentration of 0.4 mg/mL, DHB at 50 mg/ml in
methanol. One μl of each solution was loaded and mixed
directly on the target by the dried droplet method. The
analysis was performed in the linear negative ion mode
with an accelerating voltage of 20 kV and an extraction
delay of 90-80 nsec. Spectra were calibrated externally
using a peptides mix standard from Bruker Daltonics.
Methylation linkage analysis
The LOSs (about 70 mg) were degraded with 0.1 M sodium
acetate buffer, pH 4.2, at 100°C for 4 h to cleave the acid-
labile ketosidic linkage between the core OS and lipid A.
The water-insoluble lipid A was removed by centrifugation
at 20,000 g for 20 min. The oligosaccharide fraction was
precipitated from the soluble phase by adding 4 vol of −20°C
acetone [29]. Samples were centrifuged at 13,000 g at 4°C
for 20 min, and the salt-containing 80% acetone supernatant
was discarded. The pellet was dried, solubilised in dime-
thylsulfoxide, and methylated with methyl iodine [30].
Permethylated oligosaccharides were hydrolysed in 3 M
trifluoroacetic acid for 3 h at 100°C. Methylated sugars were
analysed after reduction using NaBD4 and acetylation with
an equal mixture of acetic anhydride and pyridine. Partially
methylated alditol acetates (PMAA) were analysed by
GC-MS using an agilent chromatograph 6850 equipped with
a 5975C MS detector. The neutral sugars and the glucos-
amine derivatives were separated on a SP2380 column and a
HP5-MS column, respectively.
Results
Engineered E. coli overexpressing fucosyltransferase-genes
from H. pylori produced the Lewis Y epitope and presented
it on the cell surface
In our previous work, a mutant of E. coli K12 synthesizing
a glucose-terminal truncated lipid A core was prepared by
inactivation of glycosyltransferases genes waaO and waaB
[1]. To construct strains displaying fucose-containing
structures, we additionally deleted wcaJ involved in the
assembly of colanic acid synthesis, thus providing GDP-
fucose availability under over-expression of the positive
regulator of the CPS operon (capsular polysaccharide)
named Rcsa [16]. The resulting strain was termed LPS1.
Five glycosyltransferase genes necessary for the display of
the Lewis Y antigen from different bacterial sources were
expressed heterologously: lgtE, encoding a β1,4-galacto-
syltransferase of Neisseria gonorrhoea reported to transfer
to glucose in the LOS structure of N. gonorrhoea [31]; lgtA
from Neisseria meningitidis encoding a β1,3-N-acetylglu-
cosaminyltranferase with galactose as an acceptor, and lgtB,
encoding a β1,3-galactosyltranferase with N-acetylglucos-
amine as an acceptor, also from N. meningitidis [32]. In
addition, futA and futC, encoding α1,3- and α1,2-
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Fig. 1 Cell based ELISA for the quantification of Lewis Y display on
LeY cells using a monoclonal anti-Lewis Y antibody. From left to
right: 1, no cells; 2, LPS1 cells; 3, LPS1 + pBBRlgtE; 4, LPS1 +
pBBRlgtE + pSUlgtA; 5, LPS1 + pBBRlgtE + pSUlgtA + pWKSlgtB;
6, H type II cells; 7, LX cells; 8, LY cells
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fucosyltransferases of Helicobacter pylori, respectively,
were expressed [14–16]. The transformation of the E. coli
mutant strain LPS1 with compatible plasmids carrying the
five glycosyltransferase genes should result in the produc-
tion of a modified LPS that terminates in the Lewis Y motif
Fucα-2Galβ-4[Fucα-3]GlcNAcβ-3Gal. To test this hy-
pothesis, a cell-based enzyme immunosorbent assay was
carried out with a Lewis Y specific monoclonal antibody.
Microtiter plate wells were coated with E. coli cells LPS1,
H type II, LX and LY as listed in Table 1, expressing
intermediate glycan structures between the truncated LOS
and the Lewis Y motif. Only the LY cells expressing all
necessary enzymes for Lewis Y synthesis led to a
significant signal (Fig. 1). These data indicated the display
of the Lewis Y motif at the surface of the recombinant
strain LY.
In order to visualize glycosylation of the truncated LOS
acceptor by apparent molecular weight increase of the LOS
in gel electrophoresis, a time-course experiment was carried
out with the recombinant strain expressing the glycosyl-
transferases necessary for display of the Lewis Y motif.
Cell lysates of these cells were then prepared and analysed
by Tris-Tricine polyacrylamide gel electrophoresis followed
by silver stain (Fig. 2a) and immunoblot (Fig. 2b). The
addition of monosaccharides on the LOS acceptor structure
was clearly visible by the appearance of bands with higher
apparent molecular weight over time as can be seen in the
silver nitrate stained gel which correlated with recognition
by the anti-Lewis Y monoclonal antibody in the immuno-
blot analysis. Several bands of an apparent molecular
weight intermediate of the truncated lipid A core and the
Lewis Y carrying lipid A core could be observed in the
silver nitrate staining (Fig. 2a), which suggested some
heterogeneity in the glycosylation profile, although a single
band was detected by the antibody (Fig. 2b).
Chemical analyses revealed presence but low abundance
of Lewis Y motif due to the broad specificity
of the α3-fucosyltransferase of H. pylori
In order to correlate the immunological description of the
strains generated to a chemical characterization of recom-
binant LOSs, MALDI-TOF mass spectrometry analysis was
conducted with de-O-acylated LOSs of the different E. coli
strains. This technique was proven to be suitable to
Table 2 Methylation linkage analysis of the core oligosaccharides released by mild hydrolysis from recombinant lipo-oligosaccharides
Derivativea Assignment Relative detector responseb (%)
H type II LX LY
1,5-Ac2-2,3,4-Me3-fucitol terminal Fuc 7.9 11.4 10.0
1,5-Ac2-2,3,4,6-Me4-glucitol terminal Glc 8.7 26.0 6.0
1,5-Ac2-2,3,4,6-Me4-galactitol terminal Gal 14.8 13.6 23.0
1,3,5-Ac3-2,4,6-Me3-galactitol 3-linked Gal
c 17.6 38.5 23.6
1,2,5-Ac3-3,4,6-Me3-galactitol 2-linked Gal
c 3.6 0 3.3
1,4,5-Ac3-2,3,6-Me3-glucitol 4-linked Glc 17.3 2.3 11.7
1,3,5-Ac3-2,4,6,7–Me4-heptitol 3-linked Hep
d 11.6 2.6 1.0
1,3,4,5-Ac3-2,6-Me2-glucitol 3,4-linked Glc
d 0 3.0 8.5
1,4,5-Ac3-2,3,6-Me3-glucosaminitol 4-linked GlcNAc 7.6 2.0 12.5
1,3,4,5-Ac4-2,6-Me2-glucosaminitol 3,4-linked GlcNAc 0 0.4 0.6
a According to fragmentation profiles and laboratory standards, at the exception of 3-linked Hep and 3,4-linked Glc, identified on the base of their mass
spectrum and according to the total sugar composition.
b Total ion count. Cell-specific derivatives are bolded.
c Separated one from the other with the SP2380 column only
d Separated one from the other with the HP5-MS column only.
Fig. 2 Silver-staining (A) and immunoblot analysis with a monoclo-
nal antibody against Lewis Y (B) of proteinase K-treated whole cell
extracts from the LY E. coli strain during a time-course experiment
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determine the relative abundance of bacterial LOS-
glycoforms [33]. In parallel, methylation linkage analyses
were carried out with the de-O-acylated LOSs. Results are
summarized in Table 2 and Fig. 3.
The de-O-acylated LOS sample of the LPS1 strain
contained a main species at 2015.9 Da, fitting to the
molecular composition P3-Glc-Hep2-Kdo2-lipid A as previ-
ously reported for this strain [1]. An additional species
corresponding to P3-Glc-Hep2-Kdo2-PEtN-lipid A
(+123 Da) was also observed (Fig. 3, uppermost panel).
The spectra of the three recombinant strains H type II,
LX, and LY showed progressively larger molecular weight
LOS as a result of the overexpression of recombinant
glycosyltransferase genes. All three strains overexpressed
the genes encoding for LgtE, LgtA and LgtB, which are
responsible for the synthesis of Galβ-3GlcNAcβ-3Galβ-4-
Glc-P3-Glc-Hep2-Kdo2-lipid A by glycosylation of the
truncated core present in the LPS1 strain. The MALDI-
TOF spectra of the three strains (H type II, LX, LY) showed
a common peak arising at 2542 Da (Fig. 3) from the
addition of two hexoses (Hex) and one N-
acetylhexosamine (HexNAc) to the truncated Glc-LOS of
the LPS1 strain, compatible with an additional [Gal-
GlcNAc-Gal] motif. An associated Galβ-3GlcNAcβ-
3Galβ-4Glc-P3-Glc-Hep2-Kdo2-PEtN-lipid A species was
also observed (2665 Da, Fig. 3).
The chemical analysis of the H type II strain LOS
sample. Which specifically expressed the α1,2-fucosyltrans-
ferase FutC in addition to LgtE, LgtA and LgtB contained a
peak at 2687.5 Da corresponding to an additional fucose
residue present (Fig. 3, second panel from top), matching to
the carbohydrate backbone [Fuc-Gal-GlcNAc-Gal-P3-Glc-
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Fig. 3 Negative MALDI-TOF analysis spectra of de-O-acylated LOS from recombinant E. coli strains
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Hep2-Kdo2-lipidA]. The methylation analysis (Table 2)
confirmed the presence of a terminal fucose residue as well
as 2-linked galactose, characterizing the motif Fucα-2Gal
and therefore glycoform I (Fig. 4). This is in agreement with
the specificity of FutC on β-galactosides.
When the de-O-acylated LOS sample of LX strain,
which specifically expressed the α1,3-fucosyltransferase
FutA in addition to LgtE, LgtA and LgtB, was analysed by
MALDI-TOF it resulted in a spectrum very similar to the
one of the H type II strain, although the proportion of the
mono-fucosylated species [Fuc-Gal-GlcNAc-Gal-P3-Glc-
Hep2-Kdo2-lipidA] (and the corresponding PEtN-lipidA
glycoform) was much higher (Fig. 3, second panel from
bottom). The methylation analysis revealed the presence of
a high amount of 3,4-linked glucose and a low amount of
3,4-linked N-acetylglucosamine. This indicated a fucosyla-
tion of the C3-OH of GlcNAc (in the lactosaminyl motif)
but on the other hand of the Glc residue (in the lactosyl
motif) as well, thereby demonstrating the presence of
glycoforms II and III (see Fig. 4). These data fit to the
known specificity of the fucosyltransferase FutA used in
this study, which was reported to have a good activity on
lactosyl as well as N-acetyllactosaminyl motifs of H type II
acceptors [34]. A preferential fucosylation on glucose was
also obtained when the same co-expressed enzymes acted
on free lactose as an acceptor [16]. A small glycoform at m/
z 2838 Da (Fig. 3, second panel from bottom) corresponded
to a difucosylated carbohydrate backbone [Fuc2-Gal-
GlcNAc-Gal-P3-Glc-Hep2-Kdo2-lipidA], which meant that
both the Glc and the GlcNAc residue of the Gal-GlcNAc-
Gal-P3-Glc-Hep2-Kdo2-lipidA] backbone were fucosylated,
leading to glycoform IV (Fig. 4).
The LY strain used in our study combined the two α1,2-
and α1,3- fucosyltransferases FutC and FutA, which had
been expressed separately in the strains LX and H type II.
When the de-O-acylated LOS sample of the LY strain was
analysed, the MALDI-TOF spectrum obtained was compa-
rable with the spectrum of the LX strain, but showed a
slight increase of difucosylated forms (Fig. 3, lowest panel).
The methylation analysis revealed the combined derivative
products of the α-1,2-fucosyltransferase action (2-linked
Gal) and of the α-1,3-fucosyltransferase action (3,4-linked
Glc/GlcNAc), thus corresponding to glycoforms V and VI,
the last one bearing the Lewis Y antigen (Table 2 and
Fig. 4).
Discussion
Our data show that fucosylation of the lipid A core of
Escherichia coli K12 can be obtained by design of a
suitable LOS mutant co-expressing various glycosyltrans-
ferases. This is the first report describing the endogenous
fucosylation of the lipid A core of E coli. The human cell
surface antigen Lewis Y was displayed on the bacterial cell
surface of the LY strain as visible in a cell-based
immunoassay using a monoclonal antibody raised against
Lewis Y (Fig. 1). The chemical analysis of de-O-acylated
LOS showed that the Lewis Y structure was not predom-
inant, since a major form carrying a fucose on glucose was
also observed. These data can be explained by the reduced
specificity of the α1,3-fucosyltransferase used in this study.
A possibility to increase the expression of the Lewis Y
epitope could include the use of a more specific fucosyl-
transferase. In this respect our bacterial system displaying
fucosylated structures on the cell surface would enable
researchers to sort clones (e.g. by fluorescence-activated
cell sorting) exhibiting an improved Lewis Y expression
after the molecular evolution of the α1,3-fucosyltransferase
used. It is interesting to note that, although the α1,3-
fucosyltransferase employed in this study shows relaxed
specificity towards the acceptor substrate, we can assume
that the configuration of the oligosaccharide product
created in the E. coli cells by heterologous glycosyltrans-
ferase expression is corresponding to the configuration seen
in the Lewis Y epitope e.g. on human blood cells as it is
unlikely that recognition by the monoclonal antibody
against the Lewis Y epitope would not be hindered by a
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Galβ 4GlcNAcβ 3Galβ 4Glcα 3HepII-
Fucα
3
Fucα 2Galβ 4GlcNAcβ 3Galβ 4Glcα 3HepII-
Fucα
3
Strain          Glycoform Structure
I
II
III
IV
V
VI
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3
Fucα
3
LX 
LY 
H type II 
Fig. 4 Proposed chemical structures of fucosylated LOS of recombi-
nant E. coli strains
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change configuration of the monosaccharides involved.
Earlier studies in our lab also showed that the oligosaccha-
ride product created by heterologous expression of the
α1,3-fucosyltransferase as well as the other glycosyltrans-
ferases except the α1,2-fucosyltransferase could be shown
to contain the wild type monosaccharide configuration by
NMR when produced in a soluble form [15].
The strains H type II and LX synthesized the group
H-type 2 and the Lewis X oligosaccharide motifs, respec-
tively, as judged by the chemical analysis of their respective
LOS. The fucosylation on LOS was detected by lectin-
based cell detection assays with the fucose-binding lectin of
Ralstonia solanacearum [35], but our attempt to make a
specific detection with a Lewis X antibody was not
successful.
The MALDI-TOF analysis suggests that all recombinant
strains possess PEtN-modified lipid A core species. The
PEtN substitution is normally not important in Escherichia
coli K12, but has been associated with the outer membrane
adaptation to environmental stress induced by divalent
cations and some antibiotics [36, 37]. A possible explana-
tion for the PEtN substitutions visible in our strains is that
the chimeric glycosylation of the outer core affects the outer
membrane stability, resulting in an induction of PEtN
substitution of the lipid A core.
This work is a step forward in the glyco-mimicry
engineering of bacteria. Lewis antigens are common host
targets for pathogens to bind to, such as pathogenic C.
jejuni, and P. aeruginosa [11, 12]. Competition experiments
with our fucose-displaying non-pathogenic strains therefore
might be a prelude to the design of new probiotic-based
therapies. Furthermore, these strains present the researcher
with the possibility to change the specificity of glycosyl-
transferases by molecular evolution and subsequent testing
with lectins and cell sorting. In addition, our strains could
in the future be used to study the interaction between host
receptors with the mentioned carbohydrate structures on
non-pathogenic bacteria, thereby enabling us to dissect the
effects mediated by the carbohydrate structures from the
ones mediated by other bacterial virulence factors.
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